BioCentury | Jun 11, 2015
Distillery Therapeutics

Therapeutics: Phosphoribosyl pyrophosphate synthetase 1 (PRPS1)

...ALL. In ALL cells from 358 patients who relapsed after thiopurine therapy, whole-genome sequencing identified PRPS1...
...treated with thiopurines, the activating PRPS1 mutations decreased apoptosis compared with wild-type PRPS1 or reduced-function PRPS1...
...testing the combination of lometrexol and thiopurine in mouse xenograft models of thiopurine-resistant ALL. TARGET/MARKER/PATHWAY: Phosphoribosyl pyrophosphate synthetase 1 (PRPS1)...
BioCentury | Jun 26, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer c-Myc (MYC); phosphoribosyl pyrophosphate synthetase 2 (PRPS2) Mouse studies suggest inhibiting PRPS2 could help treat cancers driven by MYC. In a Myc-dependent mouse model...
BioCentury | Jun 19, 2014
Cover Story

Breaking MYC metabolism

...is the presence of Prps1, which shares 95% homology with Prps2. The key is that Prps1...
...thwarted by redundancy and rewiring, and the fact that Prps2 is so differently regulated than Prps1...
...Institute investigator. One key to finding an inhibitor will be getting selectivity for PRPS2 over PRPS1...
BioCentury | Jan 17, 2011
Product Development

Enabling patient PRPs

After securing exclusive rights to an in vivo , patient-based screening platform for cancer-specific peptide-receptor pairs, Mercator Therapeutics Inc. needed a source of optimized peptides and antibodies. A pair of deals this month gives the biotech...
Items per page:
1 - 4 of 4